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Abstract
Purpose Indications for nipple-sparing mastectomy (NSM) have broadened to include the risk reducing setting and locally 
advanced tumors, which resulted in a dramatic increase in the use of NSM. The Oncoplastic Breast Consortium consensus 
conference on NSM and immediate reconstruction was held to address a variety of questions in clinical practice and research 
based on published evidence and expert panel opinion.
Methods The panel consisted of 44 breast surgeons from 14 countries across four continents with a background in gyne-
cology, general or reconstructive surgery and a practice dedicated to breast cancer, as well as a patient advocate. Panelists 
presented evidence summaries relating to each topic for debate during the in-person consensus conference. The iterative 
process in question development, voting, and wording of the recommendations followed the modiied Delphi methodology.
Results Consensus recommendations were reached in 35, majority recommendations in 24, and no recommendations in the 
remaining 12 questions. The panel acknowledged the need for standardization of various aspects of NSM and immediate 
reconstruction. It endorsed several oncological contraindications to the preservation of the skin and nipple. Furthermore, it 
recommended inclusion of patients in prospective registries and routine assessment of patient-reported outcomes. Consider-
able heterogeneity in breast reconstruction practice became obvious during the conference.
Conclusions In case of conlicting or missing evidence to guide treatment, the consensus conference revealed substantial 
disagreement in expert panel opinion, which, among others, supports the need for a randomized trial to evaluate the safest 
and most eicacious reconstruction techniques.
Keywords Breast cancer surgery · Nipple-sparing mastectomy · Immediate breast reconstruction
Introduction
The emphasis on esthetic outcomes and quality of life 
(QoL) after breast cancer treatment has motivated surgeons 
to develop nipple-sparing mastectomy (NSM) and immedi-
ate reconstruction. NSM was initially reserved for patients 
with small tumors, remote from the nipple, based on reports 
of high rates of nipple involvement in larger tumors [1]. 
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Indications have recently broadened to include both the risk 
reducing setting and larger tumors resulting in a dramatic 
increase in the use of NSM [2–6].
NSM reduces the adverse psychological impacts of mas-
tectomy [7]. Two large surveys of breast cancer survivors 
demonstrated similar satisfaction between mastectomy with 
reconstruction and breast-conserving surgery (BCS), even 
though the latter is considered irst choice whenever appro-
priate due to the limited extent of surgery [8, 9]. Preserva-
tion of the nipple–areola complex (NAC) improves patients’ 
post-mastectomy QoL when compared with non-nipple-
sparing mastectomies [10, 11].
Even though NSM and immediate reconstruction have 
been established in routine clinical practice with a support-
ing evidence base, many questions remain unanswered. The 
Oncoplastic Breast Consortium (OPBC) consensus confer-
ence on NSM was held to address the most urgent questions 
in clinical practice and research. The goal was to recom-
mend standard surgical approaches pertaining to NSM and 
reconstruction based on the integration of data from all types 
of clinical evidence including experience drawn from con-
temporary practice and innovations in surgery. This report 
summarizes the consensus recommendations of the panel.
Methods
Oncoplastic Breast Consortium
The OPBC is committed to bringing safe and effective 
oncoplastic breast surgery to routine patient care, namely 
oncoplastic breast-conserving surgery (OPS), as well as 
NSM and skin-sparing mastectomy (SSM) with immediate 
reconstruction [12]. After the irst consensus conference on 
standardization of OPS in German-speaking countries in 
2017, the need was recognized for an independent non-proit 
organization to develop recommendations that are applicable 
globally [13].
The core of the consortium consists of one coordina-
tor per country who recommends national panelists based 
on their scientiic and clinical record of accomplishment, 
international reputation, and motivation to support actively 
the mission of the OPBC. The selection of panelists is 
driven by evident expertise in breast cancer manage-
ment with a practice primarily dedicated to breast cancer 
at regional referral centers. The panel includes special-
ists from private, public, community, and academic set-
tings. The panel consists predominantly of oncologic and 
oncoplastic breast surgeons with a background in surgery 
and gynecology, because they meet the patients irst on 
their treatment path and have the initial discussion about 
their surgical treatment. Several reconstructive surgeons 
were included in the panel, which consists of 44 OPBC 
coordinators and panelists from 14 countries across four 
continents (see Supplementary Appendix 1).
In addition, the OPBC has a growing membership of 
surgeons from gynecologic oncology, general surgery, 
surgical oncology, and reconstructive breast surgery. The 
OPBC was founded in March 2017 and has recruited 187 
members from 46 countries within 1 year, including the 44 
coordinators and panelists. The OPBC pursues its mission 
to continuously improve OPS, NSM and SSM by bring-
ing international experts together to address controversial 
topics, by ofering oncoplastic training courses and by per-
forming relevant clinical research projects.
Preparation for the consensus conference
The expert panel of the consensus conference consisted 
of the OPBC coordinators and panelists. Before the con-
ference, the chair provided all panelists with the topics 
for debate. The pre-deined protocol of the conference 
was published on the OPBC website and was repeatedly 
updated until March 05, 2018 [14]. The panelists reviewed 
the questions for the consensus session. The organizers 
adjusted the questions according to the feedback by itera-
tive consultation over the months preceding the confer-
ence, thereby applying the modiied Delphi methodology.
Consensus conference
The OPBC consensus conference on NSM was held in 
Basel, Switzerland, on March 15, 2018. During the meet-
ing, panel members presented detailed evidence sum-
maries relating to each topic for debate, followed by an 
interactive discussion. In the second half, each group of 
questions was introduced with a short discussion, followed 
by electronic voting on the entire category of questions, 
immediate face-to-face discussion of the results, and re-
voting if appropriate.
Of the 44 OPBC coordinators and panelists who partici-
pated in the development of the set of questions, 38 (86%) 
attended the conference in person. A patient advocate was 
invited to the conference and participated in voting. Even 
though voting was restricted to the panel, all OPBC mem-
bers were able to join the meeting live online.
For most statements or questions, voting was in the for-
mat yes, no or abstain, but for a minority, the single most 
appropriate answer was selected from the list of options. 
Abstaining was recommended if panel members had a con-
lict of interest or felt that the question was not clear or 
outside of their expertise, or that the correct answer was 
missing.
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Review
References were identiied through searches of PubMed with 
the search terms “mastectomy, subcutaneous” OR “mastec-
tomy” AND “subcutaneous” OR “subcutaneous mastec-
tomy” OR “nipple” AND “sparing” AND “mastectomy” 
OR “nipple-sparing mastectomy” from January 2000 until 
April 2018. Two authors independently considered all origi-
nal series and reviews during that time period and selectively 
included additional references cited in those publications. 
Articles were also identiied through searches of the authors’ 
own iles.
Report
Simple majority was pre-defined by agreement among 
51–75% of the panelists and consensus by agreement above 
75%. The questions, answers, and discussions were brought 
into context with current evidence from the literature in the 
form of this report, which was circulated among all 44 pan-
elists in an iterative process until agreement was reached on 
each question before publication. The wording conveys the 
strength of panel support for each recommendation. Voting 
results are shown graphically in Figs. 1, 2, 3, 4, 5, and 6 and 
as exact numbers in supplementary appendices [4–9].
Results
A total of 71 questions in 18 categories covered various 
aspects of NSM with immediate reconstruction in the risk 
reducing and therapeutic setting, including oncological con-
siderations, technical indications and contra-indications, 
and outcome assessment. Consensus recommendations 
were reached in 35 questions, majority recommendations 
in 24, and no consensus and no majority in the remaining 
12 (Figs. 1, 2, 3, 4, 5, 6 and Supplementary Appendices 
4–9). The review of the literature revealed predominantly 
observational studies, with only two randomized controlled 
trials (RCTs). In the absence of supporting data from clinical 
studies, recommendations were based on personal opinion or 
preference (level III evidence according to the United States 
Preventive Services Task Force) [15].
Speciic areas in need for standardization
The irst set of questions aimed at setting the stage before 
individually assessing each question in depth in the fol-
lowing categories (Fig. 1 and Supplementary Appendix 4). 
The panel reached consensus when identifying the need 
for standardizing indications, contraindications and out-
come assessment, while a clear majority recommended 
standardization of surgical technique, type and timing of 
reconstruction in the setting of adjuvant radiotherapy and 
radiological follow-up.
Oncological safety of NSM
A clear majority of the panel felt that the oncological 
safety of NSM is comparable to conventional mastec-
tomy without reconstruction and to BCS, and the panel 
reached consensus that it is comparable to SSM if cases 
are selected appropriately (Fig.  1 and Supplementary 
Appendix 4). Residual breast tissue left behind underneath 
the skin envelope in NSM and SSM has raised concerns 
about the completeness of mastectomy [16]. The available 
evidence on oncological safety of NSM is based on obser-
vational studies of low overall quality [17]. One of the 
pioneering prospective single-center studies of 216 NSM 
patients reported loco-regional recurrence (LRR) rates of 
8.5% among irradiated and 28.4% among non-irradiated 
patients at a median follow-up of 13 years [18]. The high 
rate of LRR was primarily attributed to the non-radical 
surgical technique of subcutaneous mastectomy that was 
used at the time of recruitment between 1988 and 1994. 
In addition, the patient population included many large, 
node-positive tumors. However, more than 60 NSM series 
have been published since 2000; a selection of which is 
shown in Supplementary Appendix 2. The vast major-
ity were single-center studies. They almost all showed 
acceptable rates of recurrence after NSM. A recent analy-
sis of the Surveillance, Epidemiology, and End Results 
(SEER) database identiied 2440 breast cancer patients 
who received NSM from 1998 to 2013. The 5- and 10-year 
cancer-speciic and overall survival rates were 96.9% and 
94.9%, and 94.1% and 88.0%, respectively, very much in 
keeping with standard mastectomy techniques [19].
While a slim majority of the panel, with one-third 
abstaining, believed that the oncological safety of NSM 
is not compromised by the use of immediate fat grafting, 
there was clear consensus that safety is not compromised 
when timing is delayed (Fig. 1 and Supplementary Appen-
dix 4). The oncological safety of autologous fat grafting 
after NSM and immediate reconstruction has been widely 
debated [20]. Fat grafting can improve esthetic outcomes of 
breast reconstruction when compromised by radiotherapy, 
for example, which may translate into increased patient sat-
isfaction and psychosocial wellbeing [21, 22]. Preclinical 
studies, however, indicated that fat grafting may promote 
breast cancer growth and metastasis [23]. Several reviews 
and contemporary patient series show that fat grafting does 
not increase the risk of recurrence when applied as a delayed 
procedure after autologous reconstruction [24–27]. Finally, a 
slim majority of the panel felt that the oncological safety of 
NSM did not depend on the use of systemic therapy.
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Fig. 1  Consensus conference 
results: standardization, onco-
logical safety and indications
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Fig. 2  Consensus conference 
results: surgical technique
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Fig. 3  Consensus conference 
results: contraindications
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Fig. 4  Consensus conference 
results: special considerations in 
the risk reducing and therapeu-
tic setting
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Indications for NSM
There was consensus that NSM can be performed for any 
tumor size that does not involve the skin or nipple areola 
complex (NAC) independent of axillary status (Fig.  1 
and Supplementary Appendix 4). However, the panel was 
divided when asked if NSM could be ofered to patients 
with locally advanced breast cancer (LABC) without the 
use of successful neoadjuvant chemotherapy (NACT). 
Several groups have broadened the indication for NSM to 
include patients with LABC, who have been successfully 
down-staged with neoadjuvant systemic therapies [2, 6]. The 
evidence base for use of NSM in this setting is currently 
poor and more studies with longer follow-up are required.
The panel recommended NSM for early breast cancer 
and ductal carcinoma in situ (DCIS), and, unanimously, in 
the risk reducing setting. This latter indication is now well-
established in clinical practice [4, 5, 28].
The panel strongly felt that only specialized surgeons with 
high-volume training should perform NSM. This claim has 
been made repeatedly in the past by specialized breast and 
plastic surgeons, and should be supported by volume-out-
come research with caseload as predictor and rate of com-
plications and local recurrence as outcomes. NSM certainly 
Fig. 5  Consensus conference 
results: breast reconstruction
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is technically challenging and surgeons experience greater 
physical symptoms, mental strain, and fatigue with NSM 
than SSM [29].
Mastectomy lap necrosis
The panel strongly considered the location of the incision to 
be a risk factor for severe mastectomy lap necrosis requiring 
re-operation (Fig. 2 and Supplementary Appendix 5). This is 
supported by results of a single-center retrospective review 
of 500 NSM procedures that showed a dramatic increase 
in the risk of mastectomy lap necrosis by the use of peri-
areolar incisions, while the inframammary approach was 
associated with a decreased risk [30]. Another retrospective 
single-center study could not conirm this relationship [31].
The panel did not reach consensus or even a majority 
agreement when asked if the risk of lap necrosis depends on 
the surgical technique used for mastectomy lap dissection. 
This disagreement is mirrored by discussions in the litera-
ture. A prospective observational study at Memorial Sloan-
Kettering Cancer Center assessed risk factors for skin necro-
sis in patients undergoing uni- or bi-lateral mastectomy and 
reconstruction. They found that the use of sharp dissection 
versus cautery signiicantly increased the odds of any skin 
lap necrosis in multivariable analysis (odds ratio 5.94, 95% 
CI 2.16–16.34, p < 0.001) [32]. Another single-center study 
did not conirm this association [31]. By contrast, the panel 
reached consensus that the amount and duration of pressure 
applied by retractors during surgery play an important role.
The panel considered skin lap thickness to be associ-
ated with risk of skin necrosis, which is supported by the 
limited published evidence [33]. In this single-center ret-
rospective review, 10 NSMs with ischemic complications 
had signiicantly thinner NSM laps as measured by post-
operative magnetic resonance imaging (MRI) compared 
with 50 NSMs without ischemic complications (7.3 mm vs. 
9.0 mm, p = 0.0280).
The panel was divided on the potential benefit of 
intra-operative skin lap viability assessment: almost half 
abstained, suggesting it is rarely used clinically and the other 
half was divided on its clinical value. One single-center 
study from Japan showed a dramatic decrease in the rate 
of full-thickness skin necrosis by the use of indocyanine 
green angiography-guided skin trimming from 17.8 to 4.8% 
(p < 0.05) [34]. During the iterative question review-and-
adjust process preceding the conference, a plastic surgeon 
added a question addressing the concept of tissue pre-condi-
tioning, for example by the local application of nitroglycer-
ine. More than half of the panel abstained from a vote about 
the value of nitroglycerine, suggesting little experience in 
Fig. 6  Consensus conference 
results: registries and outcome 
assessment
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its use and very few were in favor. However, a randomized 
controlled trial (RCT) performed at the University of British 
Columbia was stopped for early success after 165 patients 
showed a diference in the rate of mastectomy lap necrosis 
of 18.5 percent in favor of nitroglycerine (p = 0.006; 95% 
CI 5.3–31.0%) [35]. The panel did not feel that early use 
of compression dressings or bras has any inluence on the 
development or the prevention of lap necrosis. There was 
strong consensus that the risk of lap necrosis depends on the 
expertise and experience of the surgeon. The organization 
and promotion of high-quality surgical training is one of the 
key missions of the OPBC.
Optimal thickness of mastectomy skin lap
There was a strong consensus that the thickness of the skin 
laps should be determined by the place and depth of the 
supericial fascia and that dissection should follow this plane 
(Fig. 2 and Supplementary Appendix 5). This is in line with 
the conclusion of a recent literature review [36]. It showed 
that the variable thickness of the subcutis precludes adop-
tion of a single speciic universal thickness for mastectomy 
skin laps.
Inframammary fold incision
The panel did not recommend the use of an inframam-
mary fold incision independent of breast size and shape, 
and was equally divided when asked if it can be used for 
tumors < 1 cm from the nipple on imaging (Fig. 2 and Sup-
plementary Appendix 5). The inframammary fold incision 
seems to be the most popular and commonly used approach 
today [37, 38]. A retrospective single-center study dem-
onstrated that reinements of surgical techniques, such as 
use of the inframammary fold incisions, can dramatically 
lower the rate of complications after NSM [39]. New and 
less invasive approaches are currently being evaluated. For 
example, a single-axillary-incision endoscopic hybrid tech-
nique was safe and associated with low morbidity and high 
patient satisfaction in an early patient series from Taiwan 
[40]. This hidden incision type can also be used for robotic 
assisted techniques that have the potential to further improve 
patient satisfaction although these techniques are not widely 
practiced at present [41, 42].
A bare majority felt that the inframammary approach 
should not be used for tumors in the upper inner quadrants in 
large breasts to avoid compromising oncological safety due 
to limited access that may increase the risk of positive mar-
gins. A retrospective analysis of a prospectively maintained 
single-center database showed that the majority of relapses 
(12 of 14; 85.7%) developed in the subcutaneous tissue of 
the quadrant where the primary tumor was located [43]. 
A large majority of the panel was of the opinion that the 
inframammary incision can be used independent of tumor 
size and location or breast size as long as the whole breast 
tissue is safely reached and removed and operative visibility 
is maintained. Finally, a majority of the panel discouraged a 
separate periareolar incision for retro-areolar frozen section 
to exclude nipple involvement before the inframammary fold 
is incised.
Oncological contraindications to preservation 
of the skin envelope
A slim majority voted that cT4b and cT4c breast cancers 
limited to a 1 × 1 cm area of skin ulceration should be a 
contra-indication to skin preservation (Fig. 3 and Supple-
mentary Appendix 6). However, other investigators have 
suggested that careful assessment of pathology and treat-
ment response may identify clinical T4 patients appropriate 
for conservation of the skin envelope [44]. A clear majority 
of the panel felt that edema of the skin with enhancement 
on imaging should be a contraindication even without red-
ness. The panel reached consensus that inlammatory breast 
cancer is an absolute contraindication even with complete 
remission of all skin changes after NACT. Half of the panel 
believed that the absence of any distance between tumor and 
skin on pre-operative imaging should be a contraindication, 
even in the absence of clinical signs of skin iniltration. A 
slim majority of panelists felt that a histological margin of 
less than 1 mm is no contraindication for the preservation 
of the skin lap, while 37% of panelists considered it a con-
traindication. During the discussion, it became obvious that 
there are wide international variations in clinical practice 
concerning positive or close margins after NSM, ranging 
from further surgery to post-mastectomy radiotherapy to 
no treatment. A large patient series at Mayo Clinic showed 
that the overall 5-year risk of local recurrence was higher in 
patients with a margin ≤ 2 mm compared to a margin > 2 mm 
(11.2% vs. 3.1%), with the proximity of the inal margin 
being an independent signiicant risk factor for local recur-
rence [45]. However, in a retrospective single-center study 
of 64 SSM procedures with a positive mastectomy margin 
towards the skin in the area of the primary tumor, only 13 
(20%) had residual cancer in simultaneous re-excisions of 
the subcutaneous tissue, suggesting a high incidence of 
false-positive margins [16].
Oncological contraindications to preservation 
of the nipple
There was strong consensus that clinical signs of nipple 
involvement and any R1 resection at the nipple margin are 
contra-indications to nipple preservation (Fig. 3 and Sup-
plementary Appendix 6). When the panel was asked if the 
nipple can be excised without the areola in patients with 
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positive retroareolar margins, no consensus was reached. A 
majority felt that radiotherapy without excision should not 
be ofered. Finally, no consensus was achieved concerning 
atypia in the margin on frozen section that is not 100% con-
sistent with the diagnosis of DCIS or invasive cancer.
Even though the clinical relevance of a positive ret-
roareolar margin is not known in the individual patient, the 
involvement of the NAC has traditionally been considered 
the main contraindication to NSM [46]. Local recurrence in 
the nipple can occur as a rare and late event after NSM. In 
a retrospective analysis of 861 patients, seven nipple recur-
rences were diagnosed on average 32 months after surgery 
[47]. In clinical practice, there are many ways to address 
a positive nipple margin: More surgery, radiotherapy (± 
boost), or observation [48]. A retrospective analysis of 217 
mastectomy patients revealed that despite a high frequency 
of malignant nipple involvement in 10.6%, less than 1% had 
involvement of the areola [49]. A center that routinely per-
formed further surgery in 46 patients with positive nipple 
margins showed that surgical practice difered considerably, 
with 51% of patients having only the nipple and 49% having 
the entire NAC excised [50].
The panel was generous in ofering to attempt nipple pres-
ervation to patients with an increased risk of occult nipple 
involvement before surgery, such as patients with a tumor-
nipple distance ≤ 1 cm or tumors > 3 cm in diameter. Tumor 
size, tumor-nipple distance, extensive DCIS component and 
multicentricity are consistent predictors of nipple involve-
ment [51, 52]. Several studies have investigated the role of 
imaging, particularly MRI and ultrasound, in predicting the 
risk of nipple involvement, and suggest a minimum dis-
tance of 1–2 cm [53–55]. However, patient selection based 
on clinicopathologic characteristics is controversial, since 
a negative retroareolar margin may exclude occult nipple 
involvement with a high negative predictive value even in 
patients at high risk [51]. This is in support of the panel 
recommendations to treat the nipple margin like any other 
margin.
While a slim majority of the panel agreed that bloody nip-
ple discharge is considered an oncological contraindication 
to nipple preservation, a clear majority felt that this does not 
apply to clear nipple discharge, since the presence of nipple 
discharge is not equivalent to NAC involvement [56].
Risk of nipple necrosis
There was a consensus recommendation that skin reduction 
techniques with NAC pedicles or free nipple grafting can 
be ofered to women with large and ptotic breasts as part 
of NSM irrespective of the type of reconstruction. A strong 
majority felt that a delayed procedure after pre-shaping 
the breast by reduction mammoplasty is a good approach. 
Indeed, several techniques have been described to reduce 
large and ptotic breasts during NSM, and the concept of 
delayed NSM after reduction mammoplasty is well sup-
ported by the literature as well [57–59].
Special considerations in the risk reducing 
and therapeutic setting
The panel did not routinely recommend sentinel lymph node 
biopsy (SLNB) during risk reducing mastectomy, in line 
with a recent review of this topic (Fig. 4 and Supplementary 
Appendix 7) [60]. A majority felt that a pre-operative MRI 
without abnormal inding is a clear reason to omit SLNB. 
There was consensus not to remove the inframammary 
fold and the soft tissue all the way to the clavicle in both 
the risk reducing and therapeutic setting; rather, the breast 
tissue should be removed according to its individual ana-
tomical borders. However, several panelists cautioned that 
personalizing the extent of surgery may have an impact on 
the efectiveness of the procedure. While the panel reached 
consensus that the fascia of the pectoral major muscle should 
not be removed during risk reducing NSM, only half of the 
panel felt that this also applies to therapeutic NSM. Simi-
larly, while there was consensus against routine retroareo-
lar frozen section in the risk reducing setting, only a bare 
majority felt that this recommendation also applies to the 
therapeutic setting.
Preferred method of breast reconstruction
While a slim majority of panelists did not use synthetic 
meshes, the panel was divided when asked if they use acellu-
lar dermal matrix (ADM; Fig. 5 and Supplementary Appen-
dix 8). The preferred method of reconstruction after NSM 
in a patient with small breasts and no planned radiotherapy 
varied widely. In fact, of eight diferent techniques, ranging 
from autologous to implant-based reconstruction with difer-
ent timings and positioning of the implants, every option was 
chosen by at least one panelist. Interestingly, one-third of 
the panel chose immediate one-stage sub-pectoral implant-
based reconstruction without synthetic mesh or ADM. The 
extensive literature on breast reconstruction after NSM has 
been summarized in Supplementary Appendix 3. The wide 
variation in clinical reconstruction practice that is mirrored 
in the literature calls for RCTs to guide treatment.
Prospective registries
There was a clear consensus that patients undergoing NSM 
should be included in national and/or international prospec-
tive registries (Fig. 6 and Supplementary Appendix 9). One 
such registry that has been recommended during the dis-
cussion is the international NSM registry INSPIRE [61]. 
Indeed, a recent review of 11 observational cohort studies 
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evaluating 7018 NSM, SSM and traditional mastectomy 
procedures concluded that these studies were of low quality 
[17]. Hence, there is a clear need for high-quality multi-
center prospective studies to assess the eicacy and safety 
of NSM [62].
Outcome assessment
The panel was unanimous in recommending the use of pre- 
and post-operative pictures as standard tool for objective 
outcome assessment after NSM (Fig. 6 and Supplemen-
tary Appendix 9), thereby recognizing the extent of such a 
commitment at high-volume centers. Since the association 
between objective esthetic outcomes and QoL is complex, 
the panel also endorsed the routine evaluation of PROs. 
The European Organisation for Research and Treatment 
of Cancer QLQ-BRECON23 questionnaire was proposed 
by one of the panelists as an internationally validated tool 
for standardized outcome assessment in patients undergo-
ing breast reconstruction [63]. Almost half of the panelists 
abstained (presumably, because this is a new and not yet 
well-known questionnaire) and the other half was divided 
when asked if this tool should be used for outcome assess-
ment. When asked about the well-established BREAST-
Q reconstruction module, a majority of the panel recom-
mended not using all scales for feasibility reasons due to 
its size, but a large majority voted for selected scales of the 
questionnaire as a standard tool for outcome assessment 
[10, 22, 64, 65].
Conclusions
The OPBC panel acknowledged the need for standardization 
of various aspects of NSM and immediate breast reconstruc-
tion. It considers the procedure safe as long as specialists, 
who select the right patients and the appropriate techniques, 
perform it. The panel endorsed several oncological contrain-
dications to the preservation of the skin and nipple. It recom-
mended inclusion of patients in prospective registries and 
evaluation of PROs as part of routine outcome assessment 
in clinical practice and research. The consensus conference 
revealed considerable heterogeneity in breast reconstruction 
practice, which is mirrored in the current literature. This 
situation calls for RCTs to evaluate the safest and most ei-
cacious reconstruction techniques.
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